New Drug Combination for Untreated Mantle Cell Lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of three drugs (sonrotoclax, zanubrutinib, and obinutuzumab) to treat mantle cell lymphoma, a type of blood cancer, in patients who have never received treatment before. The goal is to see if this combination works better and is safe for patients with aggressive forms of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mantle cell lymphoma that has never been treated before
- Your lymphoma has at least one high-risk feature (aggressive cell appearance, high Ki-67 level, or certain genetic changes)
- Your blood counts and kidney/liver function are healthy enough for treatment
- Your heart function is normal (at least 50% ejection fraction)
- You are able to swallow pills and take oral medications regularly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of three drugs—sonrotoclax, zanubrutinib, and a CD20 antibody—as a first treatment for mantle cell lymphoma. It aims to see if this new combination is safe and effective for patients who have not yet received any treatment.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Hear when a new Intermediate-to-High-Risk Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.